Clozapine REMS Program Updates: A Guide for Prescribers and Pharmacists

This resource was approved by the SMI Adviser clinical expert team for inclusion in the knowledge base.

SMI Adviser and NAMI would like to share important information with clinicians and pharmacists regarding reporting and treatment recommendation updates to the Clozapine Risk Evaluation and Mitigation Strategies (REMS) surveillance system.

This guide offers an overview of the Clozapine REMS program and transition to the new reporting system. It contains information on the changes now in effect, as well as what steps prescribers and pharmacists must follow to continue serving patients in their care.


  • Was this Helpful ?
  • YesNo

Join our #MissionForBetter now

Sign up for our newsletter. We’ll let you know about new resources, education, and more.